ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s) as per enclosed letter. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 10th November, 2021 as per the enclosed details. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2021
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2021 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2021 ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s) as per attached letter. We enclose herewith an e-mail intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its New Injectable Facility (F-3) At Karakhadi
This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our New Injectable Facility (F-3) at Karakhadi during the period from 28th January, 2021 to 6th February, 2021, indicating that the USFDA finds our responses to their observations to be adequate. USFDA has also indicated that a compliance verification would be performed during re-inspection of the said Facility in the next review cycle. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2021, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholding for the Period Ended September 30, 2021
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s) as per attached letter. We enclose herewith an e-mail intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st October, 2021 till 48 hours after the declaration of the unaudited financial results for the quarter and half year ended 30th September, 2021. The date of the Board Meeting for inter alia considering the unaudited financial results for the quarter and half year ended 30th September, 2021 will be intimated in due course. We request you to kindly take the same on record.